Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
GlobalData on MSN
MSD begins KANDLELIT-007 trial of calderasib for NSCLC
Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.
The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.
Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...
The Chosun Ilbo on MSN
Obesity treatments surpass Keytruda in global sales
Last year, sales of obesity treatments surpassed Keytruda, the immune anticancer drug that had long held the top sales ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...
One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...
Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma. Keytruda (pembrolizumab) elicited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback